D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM)

D. E. Shaw & Co. Inc. decreased its position in HUTCHMED (China) Limited (NASDAQ:HCM) by 55.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,543 shares of the company’s stock after selling 51,734 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in HUTCHMED were worth $599,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. ABC Arbitrage SA purchased a new stake in shares of HUTCHMED in the 4th quarter worth $500,000. XY Capital Ltd bought a new stake in HUTCHMED during the fourth quarter valued at about $673,000. Crossmark Global Holdings Inc. increased its position in HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock worth $268,000 after buying an additional 1,799 shares in the last quarter. Blue Trust Inc. increased its position in HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after buying an additional 3,532 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after buying an additional 2,255 shares during the period. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Trading Up 1.0%

Shares of HCM stock opened at $13.40 on Monday. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The stock has a fifty day simple moving average of $14.27 and a two-hundred day simple moving average of $14.98. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.50.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Wall Street Zen downgraded HUTCHMED from a “strong-buy” rating to a “buy” rating in a research note on Thursday. HSBC downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th.

HUTCHMED Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.